13G Filing: Opaleye Management and Inotek Pharmaceuticals Corp (ITEK)

Inotek Pharmaceuticals Corp (NASDAQ:ITEK): James A. Silverman’s Opaleye Management filed an amended 13D.

You can check out Opaleye Management’s latest holdings and filings here.

Please follow Opaleye Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Opaleye Management or update its stock holdings.

James A. Silverman
James A. Silverman
Opaleye Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Opaleye Management Inc 0 1,555,000 0 1,555,000 9 11 5.76%
0 1,555,000 0 1,555,000 9 11 5.76%
0 1,555,000 0 1,555,000 9 11 5.76%
James A. Silverman
James A. Silverman
Opaleye Management

Page 1 of 7 – SEC Filing

 

 

UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

SCHEDULE
13G

 

Under
the Securities Exchange Act of 1934

 

Inotek
Pharmaceuticals Corporation

(Name
of Issuer)

 

Common
Shares

(Title
of Class of Securities)

 

45780V102

(CUSIP
Number)

 

September
26, 2017

(Date
of Event Which Requires Filing of this Statement)

 

Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[  ]
Rule 13d-1(b)

 

[  ]
Rule 13d-1(c)

 

[  ]
Rule 13d-1(d)

 

*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.

 

The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)